78 results
424B5
URGN
UroGen Pharma Ltd
18 Jun 24
Prospectus supplement for primary offering
5:05pm
regarding the timing, progress and results of current and future nonclinical studies and clinical trials, and our research and development programs … ;
the impact of our research and development expenses as we continue developing investigational product candidates;
the future nonclinical and clinical
424B5
URGN
UroGen Pharma Ltd
17 Jun 24
Prospectus supplement for primary offering
4:19pm
research and development programs;
the clinical utility, potential advantages and timing or likelihood of regulatory filings and review decisions … and the need for additional financing;
the impact of our research and development expenses as we continue developing investigational product candidates
8-K
EX-99.1
URGN
UroGen Pharma Ltd
13 May 24
ENVISION data expected to support completion of UGN-102 NDA in Q3 2024
8:01am
31, 2024 and 2023, respectively.
R&D Expense: Research and development expenses for the first quarter of 2024 were $15.5 million, including non-cash … )
(Unaudited)
Three months ended March 31,
Revenue
Cost of revenue
Gross profit
Operating expenses:
Research and development expenses
Selling, general
8-K
EX-99.1
bn0mgqiwk53c
14 Mar 24
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
8:16am
CORRESP
spap1d
27 Nov 23
Correspondence with SEC
12:00am
UPLOAD
1ob8rk7efkslmuh
16 Nov 23
Letter from SEC
12:00am
8-K
EX-99.1
vjwx0ix2e6xjhdmojc
14 Nov 23
UroGen Pharma Reports Third Quarter 2023 Financial Results
12:00am
8-K
EX-99.1
t57kwx 69py1yvzv
10 Aug 23
UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments
8:01am
8-K
EX-99.1
r20u2xl5skvq6
11 May 23
UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments
8:05am
424B5
32eyv ujm93
1 Dec 22
Prospectus supplement for primary offering
4:05pm